Duphar Laboratories in the UK has changed its name to Solvay Healthcare. The name change is being made to give all Solvay Health companies a single identity.
Solvay Health is one of five divisions of the Belgian Solvay group, which had total world sales of $8.2 billion in 1994, and profits of $250 million. The health division is the group's fastest growing business and has sales of $1.4 billion, consisting of human and veterinary pharmaceutical products and enzymes. The group's main areas of research are central nervous system, cardiovascular, hormone replacement therapy and gastroenterology products.
In the UK, Solvay Healthcare is ranked 28th, according to the Association of the British Pharmaceutical Industry, and had turnover in 1994 of L34.7 million ($55.1 million).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze